Jasper Therapeutics, Inc.
JSPR
$0.73
$0.033.98%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -30.75% | -8.98% | -18.48% | -21.60% | 25.19% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -66.00% | -49.77% | -39.31% | -12.72% | 69.30% |
| Operating Income | 66.00% | 49.77% | 39.31% | 12.72% | -69.30% |
| Income Before Tax | 89.67% | 94.47% | 62.58% | -0.53% | -83.25% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 89.67% | 94.47% | 62.58% | -0.53% | -83.25% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 89.67% | 94.47% | 62.58% | -0.53% | -83.25% |
| EBIT | 66.00% | 49.77% | 39.31% | 12.72% | -69.30% |
| EBITDA | 65.75% | 49.21% | 39.87% | 11.46% | -70.88% |
| EPS Basic | 94.48% | 97.11% | 80.41% | 9.35% | -79.09% |
| Normalized Basic EPS | 94.48% | 97.10% | 81.47% | 18.09% | -79.09% |
| EPS Diluted | 94.48% | 97.11% | 80.41% | 9.35% | -79.09% |
| Normalized Diluted EPS | 94.48% | 97.10% | 81.47% | 18.09% | -79.09% |
| Average Basic Shares Outstanding | 87.15% | 90.86% | 90.98% | 10.90% | 2.32% |
| Average Diluted Shares Outstanding | 87.15% | 90.86% | 90.98% | 10.90% | 2.32% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |